Semaglutide
Also known as: Ozempic, Wegovy, Rybelsus
Clinical Status
FDA Approved — T2D, weight loss, CV risk, kidney protection.
Mechanism of Action
Mimics the GLP-1 hormone, slowing gastric emptying, increasing insulin secretion, reducing glucagon release, and acting on brain appetite centers to reduce hunger and increase satiety.
Dosing Defaults
Dose
1-2.4 mg weekly
Frequency
Once weekly
Administration
Subcutaneous injection weekly, or oral
Timing
Morning, same day each week
Food
with or without
Duration
Long-term / chronic use
Dose range: 0.25-2.4 mg weekly
Weekly injection — consistency of day matters more than time of day.
Side Effects
- •Nausea
- •Vomiting
- •Diarrhea
- •Constipation
- •Abdominal pain
- •Headache
- •Fatigue
- •Gallbladder problems
- •Pancreatitis
Contraindications & Warnings
- ⚠Personal/family history of medullary thyroid carcinoma
- ⚠MEN 2 syndrome
- •Not medical advice
- •BOXED WARNING: Thyroid C-cell tumors
Compare
Compare Semaglutide with another peptide side-by-side.
Ad
Related Weight Loss Peptides
This information is for educational purposes only and is not medical advice. Dosing data is based on research literature and community reports. Always consult a qualified healthcare provider before using any peptide.